NASDAQ:FLGT
Fulgent Genetics Inc Stock News
$21.39
+0.250 (+1.18%)
At Close: May 24, 2024
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
08:00am, Wednesday, 25'th Oct 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
08:00am, Tuesday, 17'th Oct 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Genetics: Navigating Post-COVID Growing Pains
05:06pm, Thursday, 21'st Sep 2023
Fulgent Genetics saw robust Q2 revenue growth at $68M but struggled with a GAAP loss of $11.2M, suggesting strategic investments. The firm boasts significant liquidity ($846.8M), allowing for potentia
Fulgent Genetics, Inc. (FLGT) Q2 2023 Earnings Call Transcript
10:33am, Friday, 04'th Aug 2023
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2023 Earnings Conference Call August 4, 2023 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Friday, 04'th Aug 2023
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.78 per share a year ago.
Fulgent Reports Second Quarter 2023 Financial Results
07:00am, Friday, 04'th Aug 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone
02:00pm, Saturday, 29'th Jul 2023
Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential unde
Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist
07:45am, Tuesday, 06'th Jun 2023
Fulgent Genetics is seeing its base of revenue shift to non-COVID testing products. It's also starting to develop medicines in house after a recent acquisition.
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
08:20am, Tuesday, 23'rd May 2023
Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches.
What To Expect From Fulgent Genetics In 2023
01:47am, Sunday, 14'th May 2023
We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its Phase 1 clinical trial evaluating the efficacy of
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
11:26am, Monday, 08'th May 2023
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
09:54am, Friday, 05'th May 2023
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $4.93 per share a year ago.
7 Stocks to Buy to Bag Big-Time Returns in Q2
02:01pm, Sunday, 16'th Apr 2023
If you're the type that runs toward danger, these stocks to buy may be right for you. To facilitate mobility, the enterprises on this list feature a market capitalization between $500 million to $2 bi
Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?
11:24am, Wednesday, 12'th Apr 2023
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?
11:25am, Thursday, 09'th Mar 2023
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.